---
layout: default
title: Interferon Beta-1B
description: "Interferon Beta-1B çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚ä¸­ç­‰è­‰æ“šç­‰ç´š L3ï¼ŒåŒ…å« 2 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 89
evidence_level: L3
indication_count: 2
---

# Interferon Beta-1B

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L3</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>2</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Interferon Beta-1bï¼šå¾å¤šç™¼æ€§ç¡¬åŒ–ç—‡åˆ° Hairy Cell Leukemia

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Interferon Beta-1B å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Interferon Beta-1b åŸæœ¬ç”¨æ–¼å¤šç™¼æ€§ç¡¬åŒ–ç—‡çš„æ²»ç™‚ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å° **Hairy Cell Leukemia** (æ¯›ç´°èƒç™½è¡€ç—…) æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **5 ç¯‡æ–‡ç»** æ”¯æŒé€™å€‹æ–¹å‘ï¼Œå…·æœ‰æ­·å²è‡¨åºŠè­‰æ“šã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | åè¦†ç™¼ä½œå‹å¤šç™¼æ€§ç¡¬åŒ–ç—‡ã€çºŒç™¼å‹å¤šç™¼æ€§ç¡¬åŒ–ç—‡ã€è‡¨åºŠå­¤ç«‹ç—‡å€™ç¾¤ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | Hairy Cell Leukemia |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.16% |
| è­‰æ“šç­‰ç´š | L3 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 1 å¼µ(3ç­†é‡è¤‡è¨˜éŒ„) |
| å»ºè­°æ±ºç­– | Consider |

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Interferon Beta-1b æ˜¯ä¸€ç¨®ç¬¬ä¸€å‹å¹²æ“¾ç´ ï¼Œå…·æœ‰å…ç–«èª¿ç¯€å’ŒæŠ—å¢æ®–æ´»æ€§ã€‚å…¶åœ¨æ¯›ç´°èƒç™½è¡€ç—…ä¸­çš„æ½›åœ¨ä½œç”¨æ©Ÿè½‰ï¼š

1. **æŠ—å¢æ®–æ•ˆæ‡‰**ï¼šå¹²æ“¾ç´ å¯ç›´æ¥æŠ‘åˆ¶è…«ç˜¤ç´°èƒå¢æ®–
2. **å…ç–«å¢å¼·**ï¼šæ´»åŒ–è‡ªç„¶æ®ºæ‰‹ç´°èƒå’Œç´°èƒæ¯’æ€§ T ç´°èƒ
3. **åˆ†åŒ–èª˜å°**ï¼šå¯èƒ½èª˜å°ç•°å¸¸ B ç´°èƒåˆ†åŒ–æˆ–å‡‹äº¡
4. **æ­·å²æ‡‰ç”¨**ï¼šBeta å¹²æ“¾ç´ æ›¾åœ¨ 1980-1990 å¹´ä»£ç”¨æ–¼ HCL æ²»ç™‚

æ­¤é æ¸¬åœ¨æ­·å²è‡¨åºŠå¯¦è¸ä¸­æœ‰æ“šå¯æŸ¥ï¼Œä½†å·²è¢«æ›´æ–°ç™‚æ³•å–ä»£ã€‚

## è‡¨åºŠè©¦é©—è­‰æ“š

**ç¾ä»£è‡¨åºŠè©¦é©—**ï¼šä¸»è¦é‡å°å¤šç™¼æ€§ç¡¬åŒ–ç—‡ï¼Œç„¡æ¯›ç´°èƒç™½è¡€ç—…ç›¸é—œè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | ç–¾ç—… |
|---------|------|------|------|
| [NCT04356339](https://clinicaltrials.gov/study/NCT04356339) | è§€å¯Ÿæ€§ | å®Œæˆ | å¤šç™¼æ€§ç¡¬åŒ–ç—‡ |
| [NCT03500328](https://clinicaltrials.gov/study/NCT03500328) | ä¸é©ç”¨ | é€²è¡Œä¸­ | å¤šç™¼æ€§ç¡¬åŒ–ç—‡ |

## æ–‡ç»è­‰æ“š

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [2082943](https://pubmed.ncbi.nlm.nih.gov/2082943/) | 1990 | è‡¨åºŠè©¦é©— | Am J Hematol | 12 å HCL æ‚£è€…ä½¿ç”¨ Beta-ser IFNï¼Œ83% åæ‡‰ç‡(7 CR, 3 PR) |
| [2736487](https://pubmed.ncbi.nlm.nih.gov/2736487/) | 1989 | å‰ç»æ€§ç ”ç©¶ | Cancer | rIFN-beta ser èˆ‡ rIFN-alpha åœ¨ HCL çš„æ¯”è¼ƒï¼Œ63% è¡€æ¶²å­¸æ”¹å–„ |
| [1702309](https://pubmed.ncbi.nlm.nih.gov/1702309/) | 1990 | å¯¦é©—å®¤ç ”ç©¶ | Br J Haematol | IFN æ²»ç™‚å¾Œæ®˜ç•™æ¯›ç´°èƒçš„ç›£æ¸¬æ–¹æ³• |
| [2198792](https://pubmed.ncbi.nlm.nih.gov/2198792/) | 1990 | ç—…ä¾‹å ±å‘Š | Am J Clin Oncol | IFN-beta æ²»ç™‚å¤±æ•—å¾Œä½¿ç”¨ DCF ä»å¯é”åˆ°å®Œå…¨ç·©è§£ |
| [3312839](https://pubmed.ncbi.nlm.nih.gov/3312839/) | 1987 | è‡¨åºŠè©¦é©— | Leukemia | UCLA ç¶“é©—ï¼šBeta-ser IFN æ²»ç™‚ HCLï¼Œ71% æ”¹å–„ç‡ |

## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›ç½²èŒç–«è¼¸å­—ç¬¬000601è™Ÿ | è²ä»–è²»éš†æ³¨å°„åŠ‘ | å‡æ™¶æ³¨å°„åŠ‘ | åè¦†ç™¼ä½œå‹å¤šç™¼æ€§ç¡¬åŒ–ç—‡ã€çºŒç™¼å‹å¤šç™¼æ€§ç¡¬åŒ–ç—‡ã€è‡¨åºŠå­¤ç«‹ç—‡å€™ç¾¤ |

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼š
  - **é‡å¤§äº¤äº’ä½œç”¨**ï¼šBupropionã€Iohexolï¼ˆé™ä½ç™²ç™‡é–¾å€¼ï¼‰
  - **ä¸­åº¦äº¤äº’ä½œç”¨**ï¼šAcarboseã€Pioglitazoneã€Simvastatinã€Rosuvastatinã€Clarithromycin ç­‰

- **å¸¸è¦‹å‰¯ä½œç”¨**ï¼š
  - é¡æµæ„Ÿç—‡ç‹€ï¼ˆç™¼ç‡’ã€å¯’é¡«ã€è‚Œè‚‰ç—›ï¼‰
  - æ³¨å°„éƒ¨ä½åæ‡‰
  - è‚åŠŸèƒ½ç•°å¸¸
  - ç™½è¡€çƒæ¸›å°‘

- **åš´é‡å‰¯ä½œç”¨**ï¼š
  - æ†‚é¬±ç—‡å’Œè‡ªæ®ºæ„å¿µ
  - åš´é‡è‚æå‚·
  - æ³¨å°„éƒ¨ä½å£æ­»

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šCoadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.
- å»ºè­°ï¼šThe risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous...


## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šConsider**

**ç†ç”±ï¼š**
Interferon Beta-1b ç”¨æ–¼æ¯›ç´°èƒç™½è¡€ç—…æœ‰ 1980-1990 å¹´ä»£çš„æ­·å²è‡¨åºŠè­‰æ“šã€‚ç•¶æ™‚ç ”ç©¶é¡¯ç¤º 63-83% çš„åæ‡‰ç‡ã€‚ç„¶è€Œï¼Œç¾ä»£ HCL æ²»ç™‚å·²æœ‰æ›´æœ‰æ•ˆçš„é¸æ“‡ï¼š

1. **Cladribine (2-CdA)**ï¼šç›®å‰ä¸€ç·šæ²»ç™‚ï¼Œå–®ä¸€ç™‚ç¨‹å¯é” 90% ä»¥ä¸Šå®Œå…¨ç·©è§£
2. **Pentostatin (DCF)**ï¼šå¦ä¸€æœ‰æ•ˆé¸æ“‡
3. **Vemurafenib**ï¼šç”¨æ–¼ BRAF V600E çªè®Šçš„é›£æ²»æ€§ HCL

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- è©•ä¼°åœ¨ç¾ä»£æ²»ç™‚å¤±æ•—æˆ–ä¸è€å—æ‚£è€…ä¸­çš„è§’è‰²
- è€ƒæ…®èˆ‡æ¨™é¶æ²»ç™‚çš„åˆä½µç™‚æ³•
- é‡æ–°å®šä½ç‚ºäºŒç·šæˆ–ä¸‰ç·šæ²»ç™‚é¸æ“‡
- é€²è¡Œç¾ä»£æ¨™æº–çš„è‡¨åºŠè©¦é©—ä»¥å»ºç«‹è­‰æ“šåŸºç¤


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Acitretin]({{ "/drugs/acitretin/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Durvalumab]({{ "/drugs/durvalumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Amcinonide]({{ "/drugs/amcinonide/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Dupilumab]({{ "/drugs/dupilumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Propantheline]({{ "/drugs/propantheline/" | relative_url }}) - è­‰æ“šç­‰ç´š L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Interferon Beta-1Bè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/interferon_beta-1b/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_interferon_beta_1b,
  title = {Interferon Beta-1Bè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/interferon_beta-1b/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
